NKT cells in the induced sputum of severe asthmatics

To determine whether there was a specific inflammatory process in severe asthmatics, the phenotypic characteristics of induced sputum immune cells were analysed among patients with severe asthma. Twenty-two induced sputa (10 severe asthmatics) were studied. Flow cytometric analysis was performed using immune cells of the sputum and monoclonal antibodies to CD3, CD4, CD8, CD56, CD25, and TCRgammadelta. The number of NKT (CD3(+) CD56(+)) cells was significantly higher in the sputum of severe asthmatics compared with mild asthmatic and healthy control groups (P < .05). CD8(+)CD56(+) cells were the predominant subtype of the increased NKT cells in severe asthmatics. CD3(+)CD56(+)Valpha24(+), TCRgammadelta(+) CD56(+), and CD4(+)CD25(+) T cells were significantly increased in severe asthmatic patients. These results suggest that the immunopathogenesis of severe asthmatics vary between severe and mild asthmatics, and that CD8(+)CD56(+) NKT cells may play an important role in the immunopathogenesis of severe asthma.     

Are exhaled nitric oxide measurements using the portable NIOX MINO repeatable?

Background

Exhaled nitric oxide is a non-invasive marker of airway inflammation and a portable analyser, the NIOX MINO (Aerocrine AB, Solna, Sweden), is now available. This study aimed to assess the reproducibility of the NIOX MINO measurements across age, sex and lung function for both absolute and categorical exhaled nitric oxide values in two distinct groups of children and teenagers.

Methods

Paired exhaled nitric oxide readings were obtained from 494 teenagers, aged 16-18 years, enrolled in an unselected birth cohort and 65 young people, aged 6-17 years, with asthma enrolled in an interventional asthma management study.

Results

The birth cohort participants showed a high degree of variability between first and second exhaled nitric oxide readings (mean intra-participant difference 1.37 ppb, 95% limits of agreement -7.61 to 10.34 ppb), although there was very close agreement when values were categorised as low, normal, intermediate or high (kappa = 0.907, p < 0.001). Similar findings were seen in subgroup analyses by sex, lung function and asthma status. Similar findings were seen in the interventional study participants.

Conclusions

The reproducibility of exhaled nitric oxide is poor for absolute values but acceptable when values are categorised as low, normal, intermediate or high in children and teenagers. One measurement is therefore sufficient when using categorical exhaled nitric oxide values to direct asthma management but a mean of at least two measurements is required for absolute values.     

Sequential events of apoptosis induced by zearalenone in cultured hepatocarcinoma cells

Zearalenone (ZEA) is a fungal metabolite that can contaminate feed and foodstuffs and can cause serious health problems for animals as well as for humans. The present investigation was conducted to determine the chronological succession of the main events that characterise ZEA-induced toxicity in human hepatocarcinoma cells. To this aim, we have monitored the effects of ZEA on (1) cell viability, (2) heat-shock protein expression, (3) oxidative damage, (4) DNA fragmentation, (5) the cell cycle and (6) the cell-death-signalling pathway. Our results demonstrated that ZEA reduced cell viability in a time- and dose-dependent manner. When we exposed HepG2 cells to 100 μM ZEA (80% of cells are viable) for different treatment times (2, 4, 8, 24, 30, 48 and 60 h), we demonstrated an induction of Hsp70 protein, an increase in reactive oxygen species (ROS) generation, DNA fragmentation and cell-cycle arrest. These events begin after only 2 h of mycotoxin exposure and are earlier than those implicated in the execution of apoptosis. However, significant apoptotic cell death was observed after at least 30 h of ZEA exposure as a consequence of increased Bax expression, decreased Bcl-2 expression and mitochondrial membrane potential (Δψm)-released cytochrome c and activated caspase-3 and caspase-9.     

Prevalence of hepatitis C virus (HCV) genotypes in Balochistan

A molecular study was conducted to investigate the prevalence of Hepatitis C virus genotypes in HCV infected population of Balochistan. Forty HCV seropositive samples belonging to seven different locations of Balochistan were collected from different health care centres. Qualitative analysis of these samples using PCR resulted in 28 positive samples. The PCR positive samples were subjected to genotyping using the method described by Ohno et al (J Clin Microbiol 35:201–202, 1997) with minor modifications. Genotyping of 28 samples revealed three different genotypes including 3a, 3b and 1a. The most prevalent genotype was 3a with rate of 50% followed by genotype 3b and 1a, respectively. Nine samples remained untyped, suggesting the need of further investigation of genotypes in this region. It has been proposed that sequencing of these samples may be helpful to unreveal these genotypes and further epidemiology of HCV genotypes. Further more, extensive and large scale studies are needed to understand the epidemiology of HCV genotypes, as no such study has been carried in this province.     

Kinetic Study of Neuropeptide Y (NPY) Proteolysis in Blood and Identification of NPY3�C35: A NEW PEPTIDE GENERATED BY PLASMA KALLIKREIN*

There is little information on how neuropeptide Y (NPY) proteolysis by peptidases occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive forms and also because the factors affecting the expression of these enzymes have been poorly studied. In the present study, LC-MS/MS was used to identify and quantify NPY fragments resulting from peptidolytic cleavage of NPY_1–36 upon incubation with human serum. Kinetic studies indicated that NPY_1–36 is rapidly cleaved in serum into 3 main fragments with the following order of efficacy: NPY_3–36 ≫ NPY_3–35 > NPY_2–36. Trace amounts of additional NPY forms were identified by accurate mass spectrometry. Specific inhibitors of dipeptidyl peptidase IV, kallikrein, and aminopeptidase P prevented the production of NPY_3–36, NPY_3–35, and NPY_2–36, respectively. Plasma kallikrein at physiological concentrations converted NPY_3–36 into NPY_3–35. Receptor binding assays revealed that NPY_3–35 is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY_3–35 may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY_3–36.Neuropeptide Y (NPY)² is a 36-amino acid peptide involved in the central and peripheral control of blood pressure (1–4) and in feeding behavior and obesity (5–9). NPY stimulates at least 6 types of receptors, called Y1, Y2, Y3, Y4, Y5, and y6 (10–12). The Y1 receptor has high affinity for full-length NPY, while Y2 and Y5 receptors bind and are stimulated by full-length and N-terminally truncated NPY. The physiological effects associated to the Y1 and Y2 receptors are the best known; exposure to a Y1 agonist causes an increase in blood pressure and potentiates postsynaptically the action of other vasoactive substances (1, 4, 13), whereas Y2 receptors are mainly located presynaptically, and upon stimulation mediate the inhibition of neurotransmitter release (14, 15). NPY is a prototype of peptide whose function can be altered by proteases. Among peptidases displaying a high affinity for NPY, the primary role appears to be played by dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5), a serine-type protease, also known as CD26, that releases an N-terminal dipeptide, Xaa-Xab- -Xac, preferentially when Xab is a proline or an alanine residue (16). By cleaving the Tyr-Pro dipeptide off the NPY N-terminal extremity, DPPIV generates NPY_3–36, a truncated form that loses its affinity for the Y1 receptor and becomes a Y2/Y5 receptor agonist (17, 18).NPY can also be degraded by aminopeptidase P (AmP, EC 3.4.11.9), a metalloprotease that hydrolyzes the peptide bond between the first and the second amino acid residue at the N terminus of proteins, if the second amino acid is a proline (19). AmP removes the N-terminal tyrosine from NPY to generate NPY_2–36, a selective Y2 agonist (18, 20). There is little information on how NPY cleavage by these enzymes occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive (NPYir) forms and also because the factors affecting the expression of these enzymes have been poorly studied. Recently, Frerker et al. (21) reported by MALDI-TOF mass spectrometry that NPY_1–36 is exclusively degraded by DPPIV into NPY_3–36 in EDTA-plasma but they did not provide kinetics of NPY cleavage efficiency of DPPIV. Beck-Sickinger and co-workers (22) studied with the same technique the metabolic stability of fluorescent N-terminally labeled NPY analogues incubated in human plasma and found that the 36th, 35th, and 33rd residues of NPY analogues may also be removed by unknown carboxypeptidases.We have set up a method using liquid chromatography coupled with tandem mass spectrometry (LC-MSⁿ) to selectively quantify NPY and its C-terminal fragments NPY_2–36 and NPY_3–36 digested by human serum. The assays used the internal standard methodology with stable isotopes NPY_1–36 (IDA) (23, 24) or porcine NPY_1–36 as internal standard.The goal of this work was: 1) to determine to which extent NPY_1–36 is degraded by proteases present in human serum and whether an inhibition of DPPIV and AmP by vildagliptin and apstatin (two specific protease inhibitors), respectively, may affect the metabolism of NPY in serum; 2) to assign kinetic values to the proteases involved in the cleavage process toward NPY; and 3) to characterize new NPY-truncated forms and to check for their possible binding capacities on NPY receptors.     

Functional monolithic platforms: Chromatographic tools for antibody purification

Polymer monoliths are an efficient platform for antibody purification. The use of monoclonal antibodies (mAbs) and engineered antibody structures as therapeutics has increased exponentially over the past few decades. Several approaches use polymer monoliths to purify large quantities of antibody with defined clinical and performance requirements. Functional monolithic supports have attracted a great deal of attention as they offer practical advantages for antibody purification, such as more rapid analysis, smaller sample volume requirements and the opportunity for a greater target molecule enrichment. This review focuses on the development of synthetic and natural polymer-based monoliths for antibody purification. The materials and methods employed in monolith production are discussed, highlighting the properties of each system. We also review the structural characterization techniques available using monolithic systems and their performance under different chromatographic approaches to antibody capture and release. Finally, a summary of monolithic platforms developed for antibody separation is presented, as well as expected trends in research to solve current and future challenges in this field. This review comprises a comprehensive analysis of proposed solutions highlighting the remarkable potential of monolithic platforms.     

Customized optical mapping by CRISPR–Cas9 mediated DNA labeling with multiple sgRNAs

Whole-genome mapping technologies have been developed as a complementary tool to provide scaffolds for genome assembly and structural variation analysis (1,2). We recently introduced a novel DNA labeling strategy based on a CRISPR–Cas9 genome editing system, which can target any 20bp sequences. The labeling strategy is specifically useful in targeting repetitive sequences, and sequences not accessible to other labeling methods. In this report, we present customized mapping strategies that extend the applications of CRISPR–Cas9 DNA labeling. We first design a CRISPR–Cas9 labeling strategy to interrogate and differentiate the single allele differences in NGG protospacer adjacent motifs (PAM sequence). Combined with sequence motif labeling, we can pinpoint the single-base differences in highly conserved sequences. In the second strategy, we design mapping patterns across a genome by selecting sets of specific single-guide RNAs (sgRNAs) for labeling multiple loci of a genomic region or a whole genome. By developing and optimizing a single tube synthesis of multiple sgRNAs, we demonstrate the utility of CRISPR–Cas9 mapping with 162 sgRNAs targeting the 2Mb Haemophilus influenzae chromosome. These CRISPR–Cas9 mapping approaches could be particularly useful for applications in defining long-distance haplotypes and pinpointing the breakpoints in large structural variants in complex genomes and microbial mixtures.     

HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies

1. Download : Download high-res image (115KB)
2. Download : Download full-size image

     

DNA damage analysis concerning GSTM1 and GSTT1 gene polymorphism in gold jewellery workers from Peshawar Pakistan

Abstract

Purpose

To evaluate the genotoxic effects of gold jewellery fumes and its association with GSTM1 and GSTT1 genetic polymorphisms.     

Sodium dodecylbenzenesulfonate–based silver nanoparticles and their potent application as antibiofilm,antimicrobial agent,and trace level determination of amlodipine

Herein, we presented the synthesis and application of sodium dodecylbenzenesulfonate–based silver nanoparticles (termed as SDBS-AgNPs). The SDBS reverse micelles (RMs) in ethanol was used as nanoreactor for green AgNPs synthesis. The size, structure, and shape of SDBS-AgNPs were well distinct by UV/visible (UV/Vis), Fourier transform infrared (FTIR) spectroscopy, dynamic light scattering (DLS), and atomic force microscopy (AFM) techniques. The SDBS-AgNPs were quite stable even at high temperature (80 °C), salt concentration (up to 300 μM), and wide pH range (2 to 12). Moreover, SDBS-AgNPs were found to be highly sensitive and selective colorimetric sensor for antihypertensive drug amlodipine (AML). The interaction of AML with SDBS-AgNPs resulted as a substantial increase in the absorbance and a prominent blue shift in wavelength from 426 to 400 nm. DLS results were further confirmed that the SDBS-AgNPs break into smaller sized particles. Similarly, FTIR results also verified the SDBS-AgNPs etching–based sensing of AML molecules due to the strong attraction by amine and carbonyl functional groups on the target drug. The proposed sensor exhibited linear response in the range of 0.001–200 μM (R² = 0.9917) with limit of detection (LOD) and quantification (LOQ) of 0.161 and 0.49 μM, respectively. The probe remained selective against AML, even in the presence of equimolar interfering species (including other drugs and metal ions). Furthermore, findings proposed that the SDBS-AgNPs might be used as effective substitute to minimize infection severity by obstructing the biofilm formation against nosocomial and urinary tract infection (UTI) causing pathogens.

Graphical abstract